Fundraising FoxBroadview Ventures — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function.
BiotechHealthtechMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder, Director)Dr. Kirthana Suresh(Founder)Sai Muralidhar Padala(Executive Officer, Director)Lori Chmura(CEO)inGowri Raman(Director)
Co-investorsEpidarex CapitalVensana CapitalGRA Venture
Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.
HardwareHealthtechMedical DevicesMontreal
Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFrançois Trudeau(Co-founder & CTO, Board Director)inPhilippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)inMaxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)inYves-Antoine Crête(Co-founder (Phase 2) & VP Technical R&D and Operations)inGabriel Georges(Co-founder & Clinical Advisor)in
Co-investorsLumira VenturesAjax HealthDesjardins CapitalBoreal VenturesCathexis VenturesFront Row Ventures+3 more
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan(Co-founder, Chief Scientific Officer)inAndrew Carek(Co-founder, Chief Technical Officer)inEric Meizlish(Chief Executive Officer)inJohn D. Martin(Chief Medical Officer)in
Co-investorsBayMed Venture PartnersCross-Border Impact VenturesLaerdal Million Lives FundOSF VenturesPortal InnovationsArboretum Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.